
Parabilis prices upsized IPO at $20 per share, raising $670M plus $75M private placement from Regeneron.
Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering (IPO) of 33.5 million shares at $20 each, expected to raise approximately $670 million. Additionally, Parabilis agreed to a ...

